Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GalenicaXSWX:GALE +0.28%82 EV-to-EBIT is 19.50 as of Jul. 22, 2026, which is 4% above its 10-year median of 18.73. GuruFocus rates XSWX:GALE with a GF Score™ of 82/100 and a GF Value™ of CHF86.40 (Fairly Valued). The stock has 1 warning sign investors should review. Among 94 Medical Distribution companies, Galenica ranks worse than 76.6% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Galenica's Enterprise Value is CHF4,598 Mil.
Galenica's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF236 Mil. Therefore, Galenica's EV-to-EBIT for today is 19.50.
The historical rank and industry rank for Galenica's EV-to-EBIT or its related term are showing as below:
XSWX:GALE'
s EV-to-EBIT Range Over the Past 10 Years
Min: 14.18 Med: 18.73 Max: 25.48
Current: 19.49
During the past 13 years, the highest EV-to-EBIT of Galenica was 25.48. The lowest was 14.18. And the median was 18.73.
XSWX:GALE's EV-to-EBIT is ranked worse than 76.6% of 94
companies
in the Medical Distribution industry
Industry Median: 12.055
vs XSWX:GALE: 19.49
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Galenica's Enterprise Value for the quarter that ended in Dec. 2025 was CHF4,999 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Galenica's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF236 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galenica EV-to-EBIT Related Terms
Galenica EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Galenica's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Galenica's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galenica EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Galenica's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Galenica's EV-to-EBIT falls into.
Galenica's current Enterprise Value is CHF4,598 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Galenica's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF236 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galenica (XSWX:GALE) has a EV-to-EBIT of 19.50 as of Jul. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Galenica and its competitors. This is near median its historical median of 18.73. Over the past decade, Galenica's EV-to-EBIT has ranged from 14.18 to 25.48. According to the industry distribution chart, Galenica ranks #72 out of 94 companies in the Medical Distribution industry, placing it in the top 76.6%.
Is Galenica's EV-to-EBIT too high?
Galenica's current EV-to-EBIT of 19.50 is near median its 10-year median of 18.73. Over the past 10 years, this metric has ranged from a low of 14.18 to a high of 25.48. The Medical Distribution industry median EV-to-EBIT is 12.06. Galenica's value of 19.50 is 61.8% above this industry median. Based on the distribution chart, Galenica ranks #72 out of 94 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Galenica has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Galenica's EV-to-EBIT compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Galenica ranks #72 out of 94 companies for EV-to-EBIT. This places Galenica in the lower half of its industry. The industry median EV-to-EBIT is 12.06. Galenica's value of 19.50 is 61.8% above this benchmark. Historically, Galenica's own EV-to-EBIT has ranged from 14.18 to 25.48 over the past decade. While the company's 10-year median is 18.73 vs. the industry median of 12.06, Galenica has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 12.06, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galenica's current EV-to-EBIT of 19.50 is 61.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Galenica and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 12.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galenica's current EV-to-EBIT is 19.50, which is near median its own 10-year median of 18.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galenica stock overvalued right now?
Based on GuruFocus' analysis, Galenica (XSWX:GALE) is currently considered Fairly Valued. The stock's GF Value™ is CHF86.40, compared to a current price of CHF89.65 — trading 3.8% above its estimated fair value. The current EV-to-EBIT is 19.50, which is near median its 10-year median of 18.73 and 61.8% above the Medical Distribution industry median of 12.06. Galenica's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Galenica (XSWX:GALE), the current EV-to-EBIT is 19.50 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Galenica (XSWX:GALE) Overvalued in 2026?
Based on GuruFocus' analysis, Galenica stock appears to be overvalued.
The current stock price of CHF89.65 is trading 3.8% above its estimated GF Value™ of CHF86.40.
GuruFocus considers Galenica to be Fairly Valued.
Key valuation signals for XSWX:GALE:
EV-to-EBIT: 19.50 (near median its 10-year median of 18.73)
GF Value™: CHF86.40 vs. price of CHF89.65 (3.8% above fair value)
Industry Position: 61.8% above the Medical Distribution median (#72 of 94)
No single metric tells the full story. See the XSWX:GALE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Galenica Ltd is an integrated healthcare service provider in Switzerland. The business is operated from two segments Products & Care and Logistics & IT. The Products & Care segment comprises the Retail business area with offerings for patients and end customers and the Professionals business area with offerings for business customers and partners in the healthcare sector. The Logistics & IT segment comprises the two sectors Wholesale and Logistics & IT Services. These provide services for all those involved in the healthcare sector - pharmacies, drugstores, doctors, hospitals and care homes, partners, and suppliers. Geographically, it operates in Switzerland and Other Countries.
82GF Score
Get the complete analysis for XSWX:GALE
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:GALE has been successfully added to your 
